Medicine and Dentistry
Hepatocellular Carcinoma
100%
Nuclear Factor
100%
Alternative Complement Pathway C3 C5 Convertase
100%
Piperidone Derivative
100%
Proteasome
36%
Carcinoma Cell
27%
Programmed Cell Death
18%
Xenograft
18%
Endoplasmic Reticulum Stress
18%
Proteasome Inhibitor
18%
In Vitro
9%
Disease
9%
Malignant Neoplasm
9%
Cancer Cell
9%
Cell Death
9%
Anticarcinogen
9%
Tumor Progression
9%
Hepatocellular Carcinoma Cell Line
9%
Titrimetry
9%
Tyrosine-Kinase Inhibitor
9%
Multiple Myeloma
9%
Receptor Subunit
9%
Cysteine
9%
Bortezomib
9%
Sorafenib
9%
Ubiquitin
9%
Biochemistry, Genetics and Molecular Biology
Proteasome
100%
Complement Factor B
100%
Endoplasmic Reticulum Stress
50%
Proteasome Inhibitor
50%
Mouse
25%
Cancer Cell
25%
Mouse Model
25%
Anticancer
25%
Cysteine
25%
Tyrosine Kinase Inhibitor
25%
Metabolic Pathway
25%
Sorafenib
25%
Cell Death
25%
Tumor Progression
25%
Eicosanoid Receptor
25%
Ubiquitin
25%
Pharmacology, Toxicology and Pharmaceutical Science
Liver Cell Carcinoma
100%
Alternative Complement Pathway C3 C5 Convertase
100%
Nuclear Factor
100%
Piperidone Derivative
100%
Proteasome
33%
Malignant Neoplasm
16%
Proteasome Inhibitor
16%
Anticarcinogen
8%
Mouse
8%
Mouse Model
8%
Tumor Growth
8%
Cysteine
8%
Protein Tyrosine Kinase Inhibitor
8%
Sorafenib
8%
Receptor Subunit
8%
Bortezomib
8%
Disease
8%
Inflammation
8%
Ubiquitin
8%
Multiple Myeloma
8%
Immunology and Microbiology
Complement Factor B
100%
Proteasome
100%
Carcinoma Cell
50%
Xenograft
33%
Endoplasmic Reticulum Stress
33%
Mouse
16%
Cancer Cell
16%
Cell Death
16%
Mouse Model
16%
Hepatocellular Carcinoma Cell Line
16%
Sorafenib
16%
Multiple Myeloma
16%